Genetic Technologies Limited

179 articles about Genetic Technologies Limited

• GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment

  10/18/2023

  Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of a peer-reviewed research paper validating geneType’s Pancreatic Cancer risk assessment test.

• GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network

  9/27/2023

  Genetic Technologies Limited – a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce a partnership with the Gold Coast Private Hospital, a member of Healthscope, to establish a Precision Medicine Clinic at the hospital.

• GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry PartnerTrial to Assess Multi Cancer Genetic Risk Assessment in General Practice

  9/11/2023

  Genetic Technologies Limited is pleased to announce that a Medical Research Future Fund Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations.

• Annual Results – Momentum Building on our Commercial Plans

  8/30/2023

  Genetic Technologies Limited, a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2023.

• Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume

  7/28/2023

  Genetic Technologies Limited, a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to provide this Quarterly Business Update for the quarter ending 30 June 2023.

• Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

  7/21/2023

  Genetic Technologies Limited advises that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

• New Publication Validates geneType for Melanoma Risk Assessment

  4/28/2023

  Genetic Technologies Limited is pleased to announce the publication of a research paper in the peer-reviewed journal Melanoma Research validating the geneType for Melanoma risk assessment test in one of the most commonly diagnosed cancers in the Western world, 3rd in Australia and 5th in the United States.

• Quarterly Business Update – March 2023

  4/27/2023

  Genetic Technologies Limited, a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 31 March 2023.

• GeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial Fibrillation

  3/27/2023

  Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the US launch of three (3) new diseases taking the total number of individual risk assessments included in the geneType Multi-Test to nine (9), all from the one simple saliva sample.

• New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

  2/9/2023

  Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment.

• Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

  2/6/2023

  Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update.

• Genetic Technologies Announces $5 Million Registered Direct Offering

  2/3/2023

  Genetic Technologies Limited today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 3,846,155 American Depositary Shares.

• GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

  2/3/2023

  Genetic Technologies Limited is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer.

• Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth

  1/30/2023

  Genetic Technologies Limited, a global leader in guidance-driven genomics-based tests in health, wellness and serious diseases releases its Quarterly business update for the quarter ended 31 December 2022.

• Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium

  1/24/2023

  Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce a poster presentation by Dr Erika Spaeth at the prestigious American Society of Clinical Oncology Gastroenterology Cancer Symposium in San Francisco last weekend.

• Genetic Technologies Provides Business Update

  1/11/2023

  Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to provide the following business update for the first half of the 2023 financial year.

• GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes

  12/6/2022

  Genetic Technologies Limited is delighted to announce the publication of a peer-reviewed paper describing the development and validation of the polygenic risk scores that underlie the risk predictions for cardiovascular diseases and type 2 diabetes in the geneType Multi-Risk Test.

• Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease

  11/10/2022

  Genetic Technologies, a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be hosting an interview between Dr Erika Spaeth and Adjunct Professor Charles Siles Health.

• Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention

  11/9/2022

  Genetic Technologies Limited, a global leader in guideline driven genomics-based tests in health, wellness and serious disease is delighted to announce the publication of a validation study evaluating the performance of the geneType ovarian cancer test.

• Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details

  10/25/2022

  Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended September 30, 2022 (Q1 FY23).